Latest Share Purchase Plan News

Latrobe Magnesium Limited has successfully closed an oversubscribed Share Purchase Plan, raising $836,800 to fund its Demonstration Plant operations in Victoria. This capital injection supports the company’s pioneering sustainable magnesium extraction efforts.

Proteomics International Laboratories Ltd is raising up to $5.5 million through a $4 million placement and a $1 million Share Purchase Plan at $0.37 per share, offering shareholders a discounted entry and free attaching options.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

Saturn Metals has significantly upsized its Share Purchase Plan to $9.25 million, raising total capital of $32.25 million to accelerate development of its Apollo Hill Gold Project and expand exploration in Western Australia.

Rox Resources has raised A$40 million through a strongly supported institutional placement to accelerate early development works at its high-grade Youanmi Gold Project, significantly de-risking the pathway to production.

Galan Lithium Limited has launched a $4 million Share Purchase Plan for existing shareholders following a $13 million institutional placement, aiming to bolster its capital base at a consistent share price of $0.11.

BluGlass Limited has launched a $6 million Share Purchase Plan (SPP) offering new shares with attaching options to eligible shareholders, aiming to fund the scale-up of its visible laser production and support ongoing product development.

Elixir Energy has successfully closed its Share Purchase Plan, raising an additional $117,000 and bringing total capital raised to $7.1 million, supported by new shares and free attaching options.

BluGlass has completed a $2.3 million placement and launched a $6 million Share Purchase Plan to fund scaling of its GaN laser production, targeting high-growth sectors including quantum sensing and defense.

Sparc Technologies has successfully raised up to A$2.7 million through a share placement and a Share Purchase Plan, positioning the company to accelerate commercialisation of its graphene additive ecosparc and support its green hydrogen pilot projects.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.

4DS Memory Limited has successfully manufactured its first 20nm memory cell array, marking a pivotal step in its ReRAM technology development, while raising $8.6 million through a placement and Share Purchase Plan to fuel ongoing innovation.